Table 3.
The implication of histone acetylase inhibitors(HDACis) in CRC treatment
| Class | Specificity | HDACis | Experiment design | Effect | Reference |
|---|---|---|---|---|---|
| Hydroxamic acids | Class I, II | Trichostatin A (TSA) | CRC cell lines | Inhibit CRC cells growth | [87] |
| Vorinostat (SAHA) | Mouse model | Inhibit the growth of colon tumors in nude mice | [88] | ||
| CRC cell lines | Anti-proliferative in CRC cell lines | [89] | |||
| Panobistat | CRC cell lines HCC cell lines | Anti-angiogenic Reduce proliferation | [98] | ||
| Belinostat | CRC cell lines | Induce CRC cell apoptosis | [97] | ||
| Short-chain fatty acids | Class I | Butyrate | CRC cell lines | Inhibit CRC cell migration and invasion | [93] |
| Valproic acid (VPA) | CRC cell lines | Inhibit the growth of CRC cell lines with cell cycle arrest | [90] | ||
| Benzamides | Class I | Entinostat (MS-275) | CRC cell lines mouse model | Anti-proliferative effects | [94] |
| Benzoic acid | Dihydroxy benzoic acid | Colon cell lines | Induce cancer cell death | [96] | |
| Cyclic peptides | Class I, II | Romidepsin (FK228) | CRC cell lines | Anti-tumor activity | [91] |